This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
November 05, 2018
Strongbridge Biopharma plc to Present at the Stifel 2018 Healthcare Conference
November 02, 2018
Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® plus Rituximab in Follicular Lymphoma
November 01, 2018
Vicore Pharma’s rights issue registered – conversion of BTA to shares
November 01, 2018
Nordic Nanovector: Promising results from preclinical studies with a novel CD37-targeted alpha therapy for B-cell tumours to be presented at ASH
November 01, 2018
Nordic Nanovector highlights promising clinical results from Phase 1/2 trial of Betalutin® in relapsed/refractory indolent non-Hodgkin’s lymphoma
November 01, 2018
Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018
November 01, 2018
BONESUPPORT HOLDING AB (publ) – Q3 2018 Interim Report – invitation to conference call and webcast
November 01, 2018
Targovax ASA: Third quarter 2018 results
October 31, 2018
Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update
October 31, 2018
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)